FDA Rejects Latest Effort To Treat PTSD With MDMA

By Sam Reisman · August 9, 2024, 8:18 PM EDT

The U.S. Food and Drug Administration has rejected a new drug application to treat post-traumatic stress disorder with the psychedelic drug MDMA, an entactogen also known as ecstasy or molly, the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Sam

December 20, 2024
Psychedelics Law Reformers Hit Multiple Setbacks In 2024
December 16, 2024
With Legal Battle Looming, Neb. Legalizes Medical Marijuana
December 11, 2024
Neb. Medical Pot Legalization Hit With New Legal Challenge
November 06, 2024
Cannabis And Psychedelic Reform Bids Fail In Multiple States
September 05, 2024
Lawmakers, AGs Urge Justices To OK Denial Of E-Cig Apps
August 30, 2024
Nebraska Expected To Vote On Medical Marijuana Legalization
July 30, 2024
Psychedelics And The Law: A Midyear Review
June 04, 2024
FDA Advisers Rebuff Bid To Treat PTSD With MDMA
May 02, 2024
State Legislators Urge Feds To Change Cannabis' Status
April 18, 2024
FDA Head Gets GOP Rep.'s Rebuke Over Pot Rescheduling